Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis
Main finding · Hip fractureResult — go to the resultHazard ratio 0.83 95% CI 0.70–0.98Authors' conclusion
There were significantly lower rates of hip and nonvertebral fractures with abaloparatide compared to teriparatide, which were consistent across subgroups. No differences in cardiovascular safety were noted between cohorts.
Study context
- Population
- Women aged ≥50 years initiating abaloparatide or teriparatide, anonymized claims data (ICON's Symphony Health, PatientSource)21,676 per cohort, matched
- Participants
- 21,676 vs 21,676
- Exposure
- Abaloparatide vs teriparatide
- Abaloparatiden = 21,676
- Teriparatiden = 21,676reference
- Outcome
- Time to first hip fracture, nonvertebral fracture and serious cardiovascular event
- Follow-up
- 18 months (+ 30 days )
Methodological detailsclaims data, propensity score-matched cohorts, Cox proportional hazards models
- Claims data
- Propensity score-matched cohorts
- Cox proportional hazards models
Main finding
Hip fracture
Hazard ratio
0.83
95% CI 0.70–0.98
P = 0.027
Events by group
Abaloparatidevs Teriparatide
HR 0.83 (95% CI 0.70–0.98); P = 0.027
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Abaloparatide | Teriparatide | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Nonvertebral fracture · 18 months (+ 30 days follow-up) | 4.4% | 5.0% | 0.88 (0.80–0.96) | P = 0.003 | |
| 0.512Hazard ratio (log scale) |
Treatment exposure >12 months
Treatment-subgroup interactions (age, prior antiresorptive use, prior fracture)
- No significant treatment-subgroup interactions
- P ≥ 0.2
Safety
Serious cardiovascular events
- Cardiovascular events were similar between groups
Original publication
Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis. Endocr Pract. Published 16 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →